H&E

Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, March 18, 2024
Singular, Growth, SAN, Tissue, NGS, RNA, Proteomics, Workflow, Investment, Genomics, OMIC, Network throughput, H&E, Video game

“We ended 2023 on a strong note, shipping our largest number of quarterly instruments to-date,” said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics.

Key Points: 
  • “We ended 2023 on a strong note, shipping our largest number of quarterly instruments to-date,” said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics.
  • Shipped eight G4 systems in the fourth quarter of 2023, increasing the total number of commercial systems shipped to 24 as of the end of the fourth quarter of 2023.
  • Operating expenses for the fourth quarter of 2023 totaled $24.8 million, compared to $22.5 million for the fourth quarter of 2022.
  • Operating expenses included non-cash stock-based compensation of $2.7 million for the fourth quarter of 2023 and $3.1 million for the fourth quarter of 2022.

Nucleai Unveils Breakthrough AI Spatial Biomarker Advancements at AACR 2024 with the Potential to Transform Cancer Diagnostics and Treatments

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Other Science, Research, Artificial Intelligence, Genetics, Science, Diagnosis, Lung cancer, Algorithm, Immunotherapy, Patient, 2.0, University of Queensland, Biomarker, Tumor microenvironment, Marie Cassidy, Cancer, University, AI, Doctor of Philosophy, Medicine, AACR, Neoplasm, Drug development, Pathology, Therapy, Translational medicine, H&E, Medical imaging

Nucleai's posters will highlight novel AI spatial biomarkers and enhanced histopathology workflows that promise to revolutionize cancer treatment and diagnostics.

Key Points: 
  • Nucleai's posters will highlight novel AI spatial biomarkers and enhanced histopathology workflows that promise to revolutionize cancer treatment and diagnostics.
  • Leveraging Nucleai's unique AI spatial biology solution, the research uncovered the correlation between the metabolic state and spatial distribution of tumor and immune cells in the tumor microenvironment, shedding new light on treatment outcomes and potential resistance mechanisms.
  • Nucleai is driving innovation in cancer research and collaborating with leading scientists to translate these findings into tangible benefits for patients and healthcare providers worldwide.
  • By integrating spatial biology with AI, Nucleai creates actionable insights from complex pathology data, setting a new standard for diagnosis and treatment, and advancing precision medicine.

10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay

Retrieved on: 
Tuesday, March 26, 2024
Transcriptome, Histology, 10x Genomics, History, Space Ranger, Integration, Genomics, H&E, Gene expression, Microscope

PLEASANTON, Calif., March 26, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Visium HD Spatial Gene Expression product. This assay enables researchers to measure the whole transcriptome from FFPE tissue sections at single cell-scale resolution.

Key Points: 
  • Began global shipments for Visium HD, a new product that enables whole transcriptome spatial discovery at single cell–scale resolution
    PLEASANTON, Calif., March 26, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Visium HD Spatial Gene Expression product.
  • "Visium HD is a game-changer for spatial discovery research, and our team couldn't be more proud and excited to get this long-awaited product into the hands of our customers," said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics.
  • Combining the power of whole transcriptome spatial discovery with histological insights, Visium HD enables comprehensive characterization of FFPE tissue samples.
  • Best-in-class sequencing-based spatial transcriptomics data: Map gene expression with precision and high confidence using a simple and robust workflow exclusively available on Visium CytAssist.

H&E Equipment Services, Inc. Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, February 22, 2024
Commercial Building & Real Estate, Construction & Property, Building Systems, Machine Tools, Metalworking & Metallurgy, Urban Planning, REIT, Manufacturing, Residential Building & Real Estate, Acquisition, Total, OEC, Adobe Acrobat, Growth, Renting, Sale, FINANCIAL, Net income, H&E, Komatsu, GAAP, Tax, Eastern Time Zone, Security (finance), Depreciation, Video game

Gross profit increased 16.9% in the fourth quarter of 2023 to $186.3 million compared to $159.4 million in the fourth quarter of 2022.

Key Points: 
  • Gross profit increased 16.9% in the fourth quarter of 2023 to $186.3 million compared to $159.4 million in the fourth quarter of 2022.
  • On average, rental rates in the fourth quarter of 2023 were 3.8% better than rates in the fourth quarter of 2022.
  • Dollar utilization for the fourth quarter of 2023 was 40.3% compared to 41.9% in the fourth quarter of 2022.
  • Interest expense was $16.3 million for the fourth quarter of 2023 compared to $13.5 million in fourth quarter of 2022.

H&E Equipment Services Announces 2023 Fourth Quarter Earnings and Conference Call Date

Retrieved on: 
Thursday, February 15, 2024
Eastern Time Zone, H&E, Adobe Acrobat

, Feb. 15, 2024 (GLOBE NEWSWIRE) -- H&E Equipment Services, Inc. (NASDAQ: HEES) today announced that it will release its 2023 fourth quarter financial results before the market on Thursday, February 22, 2024.

Key Points: 
  • , Feb. 15, 2024 (GLOBE NEWSWIRE) -- H&E Equipment Services, Inc. (NASDAQ: HEES) today announced that it will release its 2023 fourth quarter financial results before the market on Thursday, February 22, 2024.
  • The Company will also hold a conference call to discuss fourth quarter results on Thursday, February 22, 2024, at 10:00 a.m. (Eastern Time).
  • To listen to the call, participants should dial 844-887-9400 approximately 10 minutes prior to the start of the call.
  • The live broadcast of H&E Equipment Services’ quarterly conference call will be available online at www.he-equipment.com on February 22, 2024, beginning at 10:00 a.m. (Eastern Time) and will continue to be available for 30 days.

H&E Equipment Services, Inc. Completes Acquisition of Precision Rentals

Retrieved on: 
Tuesday, January 2, 2024
Other Construction & Property, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Building Systems, Urban Planning, REIT, Acquisition, Growth, Precision, H&E

H&E Equipment Services, Inc. (“H&E” or the “Company”) (NASDAQ: HEES) today announced the completion of its acquisition of the business of Precision Rentals (“Precision”).

Key Points: 
  • H&E Equipment Services, Inc. (“H&E” or the “Company”) (NASDAQ: HEES) today announced the completion of its acquisition of the business of Precision Rentals (“Precision”).
  • The acquisition improves H&E’s branch density in the Phoenix and Denver metropolitan areas and adds a young and attractive mix of equipment totaling approximately $70 million in original equipment cost.
  • This strong growth has been accomplished through our successful warm start program and the acquisition of attractive and well-managed companies, such as Precision, with its excellent operations in Phoenix and Denver, and the surrounding areas.
  • These two promising geographic regions are identified among the 20 largest metropolitan statistical areas in the U.S. and represent excellent non-residential construction potential.

H&E Equipment Services Signs Definitive Agreement To Acquire Phoenix-based Precision Rentals

Retrieved on: 
Monday, December 11, 2023
Other Construction & Property, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Building Systems, Urban Planning, Landscape, H&E, City, Acquisition, Phoenix

H&E Equipment Services, Inc. (“H&E” or the “Company”) (NASDAQ: HEES) today announced the signing of a definitive agreement to acquire the business of Precision Rentals (“Precision”).

Key Points: 
  • H&E Equipment Services, Inc. (“H&E” or the “Company”) (NASDAQ: HEES) today announced the signing of a definitive agreement to acquire the business of Precision Rentals (“Precision”).
  • Based in Phoenix, Arizona, the company operates a branch in Phoenix and a second location in Aurora, Colorado.
  • Precision offers a mix of general rental assets with a total fleet size, as measured by original equipment cost, of approximately $70 million and an attractive average fleet age of 37 months.
  • Brad Barber, chief executive officer of H&E Equipment Services, Inc., identified compelling strategic benefits associated with the acquisition, citing, “Since 2006, Precision Rentals has successfully grown its equipment rental business through a focus on reliability, fleet diversity and exceptional customer service.

AI-Powered TIL Analysis by Lunit Unveils Prognostic Insights for Colon Cancer - published in npj Precision Oncology

Retrieved on: 
Monday, November 27, 2023
WSI, H&E, STIL, Patient, Tumor microenvironment, ITIL, TME, Therapy, Prognosis, Cancer, Analyser, Biomarker, Recurrence, AI, Neoplasm, TIL, Medical imaging, Medical device

SEOUL, South Korea, Nov. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, published a new study in npj Precision Oncology (Nature Partner Journal) , using Lunit SCOPE IO to predict prognosis in stage II–III colon cancer via AI-powered spatial analysis of tumor-infiltrating lymphocytes (TIL).

Key Points: 
  • SEOUL, South Korea, Nov. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, published a new study in npj Precision Oncology (Nature Partner Journal) , using Lunit SCOPE IO to predict prognosis in stage II–III colon cancer via AI-powered spatial analysis of tumor-infiltrating lymphocytes (TIL).
  • This study showed that Lunit SCOPE IO and the power of AI for spatial TIL analysis can provide clinicians with a practical and efficient tool to enhance prognosis prediction.
  • Traditionally recognized as a biomarker that can be related to cancer prognosis, TIL densities in the tumor microenvironment (TME) offer valuable insights into the patient's immune response to the tumor.
  • This result suggests that AI-powered TIL analysis can provide practical and reliable prognostic information for stage II–III colon cancer.

H&E Equipment Services Expands Presence in Central and Southern California, Acquires Rental Assets of Giffin Equipment

Retrieved on: 
Wednesday, November 1, 2023
Other Construction & Property, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Building Systems, Urban Planning, REIT, H&E, City, Acquisition, Lease

H&E Equipment Services, Inc. (“H&E” or the “Company”) (NASDAQ: HEES) today announced the acquisition of the equipment rental assets of Giffin Equipment (“Giffin”), a California-based provider of non-residential construction and industrial equipment.

Key Points: 
  • H&E Equipment Services, Inc. (“H&E” or the “Company”) (NASDAQ: HEES) today announced the acquisition of the equipment rental assets of Giffin Equipment (“Giffin”), a California-based provider of non-residential construction and industrial equipment.
  • The acquisition, which closed earlier today, includes three branch locations and a fleet size, as measured by original equipment cost, of approximately $13.4 million.
  • Brad Barber, chief executive officer of H&E Equipment Services, Inc., detailed the importance of the acquisition, stating, “The addition of Giffin’s equipment rental assets and facilities increases our branch density and assists in bridging our existing locations in Central and Southern California.
  • Throughout Giffin’s 93-year history in California, its employees have maintained a focus on strong customer service, reliable equipment, and equipment solutions.

Ultivue announces launch of new configurable multiplex spatial panels at the Society for Immunotherapy of Cancer 2023 meeting

Retrieved on: 
Monday, October 30, 2023
Research, Biomarker, Society for Immunotherapy of Cancer, Product management, Cell, Drug development, SITC, Immunotherapy, Workflow, H&E, Society, Associate, Vaccine, Medical imaging

Pre-optimized ready-to-use kits with OmniVUE panels will be delivered within four weeks of request, with no additional development costs.

Key Points: 
  • Pre-optimized ready-to-use kits with OmniVUE panels will be delivered within four weeks of request, with no additional development costs.
  • Ultivue's biomarker library currently includes 24 validated immune biomarkers with additional biomarkers of clinical relevance being added continually.
  • OmniVUE panels leverage Ultivue's proprietary InSituPlex ® platform technology to enable a fast and simple assay workflow with high-quality, reliable, and quantitatively verified assay performance.
  • To learn more about OmniVUE, you can reach out to the Ultivue team through the media contacts below or register to attend the OmniVUE product launch event at SITC 2023.